Over the past 12 months, 14 insiders at VERTEX PHARMACEUTICALS INC / MA filed 95 open-market SEC Form 4 transactions on VRTX: 4 purchases worth $5.8M and 91 sales worth $154.0M. Insiders have been net sellers over this period. The most recent filing was on Jul 2, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 2, 26 | Duncan McKechnieEVP, Chief Commercial Officer | SELL | 1.5K | $519.00 | $800K |
| Jul 2, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 1.5K | $524.99 | $787K |
| Jul 1, 26 | Joy LiuEVP and Chief Legal Officer | SELL | 828 | $502.71 | $416K |
| Jun 26, 26 | Carmen BozicEVP and CMO | SELL | 596 | $482.50 | $288K |
| Jun 18, 26 | Carmen BozicEVP and CMO | SELL | 1.0K | $462.17 | $471K |
| Jun 15, 26 | Carmen BozicEVP and CMO | SELL | 4.1K | $450.00 | $1.8M |
| Jun 5, 26 | Carmen BozicEVP and CMO | SELL | 1.7K | $450.00 | $785K |
| May 29, 26 | Carmen BozicEVP and CMO | SELL | 2.0K | $450.00 | $888K |
| May 15, 26 | Carmen BozicEVP and CMO | SELL | 1.4K | $453.45 | $614K |
| May 15, 26 | Mark E. BunnageEVP, Chief Scientific Officer | SELL | 33 | $453.45 | $15K |
| May 12, 26 | Carmen BozicEVP and CMO | SELL | 7.0K | $450.00 | $3.1M |
| May 4, 26 | Sangeeta N. Bhatia | SELL | 318 | $423.73 | $135K |
| Mar 27, 26 | Carmen BozicEVP and CMO | SELL | 2.3K | $450.95 | $1.1M |
| Mar 13, 26 | Carmen BozicEVP and CMO | SELL | 2.3K | $481.79 | $1.1M |
| Mar 11, 26 | Duncan McKechnieEVP, Chief Commercial Officer | SELL | 2.6K | $498.42 | $1.3M |
| Mar 4, 26 | Duncan McKechnieEVP, Chief Commercial Officer | SELL | 2.4K | $475.30 | $1.2M |
| Mar 2, 26 | Joy LiuEVP and Chief Legal Officer | SELL | 892 | $495.96 | $442K |
| Feb 27, 26 | Carmen BozicEVP and CMO | SELL | 2.3K | $480.31 | $1.1M |
| Feb 27, 26 | Reshma KewalramaniCEO & President | SELL | 15.6K | $496.95 | $7.7M |
| Feb 26, 26 | Kristen AmbroseSVP & Chief Accounting Officer | SELL | 357 | $483.36 | $173K |
| Feb 25, 26 | Kristen AmbroseSVP & Chief Accounting Officer | SELL | 223 | $486.35 | $108K |
| Feb 25, 26 | Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off. | SELL | 668 | $486.35 | $325K |
| Feb 25, 26 | Jonathan BillerEVP and Chief Legal Officer | SELL | 945 | $486.35 | $460K |
| Feb 25, 26 | Mark E. BunnageEVP, Chief Scientific Officer | SELL | 620 | $486.35 | $302K |
| Feb 25, 26 | Duncan McKechnieEVP, Chief Commercial Officer | SELL | 2.5K | $489.00 | $1.2M |
| Feb 25, 26 | Amit SachdevEVP Chief Patient & Ext Af Off | SELL | 1.8K | $486.35 | $898K |
| Feb 25, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 260 | $486.35 | $126K |
| Feb 19, 26 | Amit SachdevEVP Chief Patient & Ext Af Off | SELL | 19.7K | $471.43 | $9.2M |
| Feb 18, 26 | Kristen AmbroseSVP & Chief Accounting Officer | SELL | 638 | $473.68 | $302K |
| Feb 18, 26 | Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off. | SELL | 817 | $473.68 | $387K |
| Feb 18, 26 | Jonathan BillerEVP and Chief Legal Officer | SELL | 1.2K | $473.68 | $589K |
| Feb 18, 26 | Mark E. BunnageEVP, Chief Scientific Officer | SELL | 1.2K | $473.68 | $560K |
| Feb 18, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 368 | $473.68 | $174K |
| Feb 17, 26 | Kristen AmbroseSVP & Chief Accounting Officer | SELL | 1.6K | $489.46 | $762K |
| Feb 17, 26 | Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off. | SELL | 2.0K | $489.46 | $994K |
| Feb 17, 26 | Jonathan BillerEVP and Chief Legal Officer | SELL | 2.5K | $489.46 | $1.2M |
| Feb 17, 26 | Mark E. BunnageEVP, Chief Scientific Officer | SELL | 2.4K | $489.46 | $1.2M |
| Feb 17, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 609 | $489.46 | $298K |
| Feb 13, 26 | Sangeeta N. BhatiaDirector | SELL | 266 | $500.00 | $133K |
| Feb 13, 26 | Jonathan BillerEVP and Chief Legal Officer | SELL | 988 | $499.00 | $493K |
| Feb 13, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 1.5K | $499.99 | $750K |
| Feb 11, 26 | Kristen AmbroseSVP & Chief Accounting Officer | SELL | 1.4K | $460.43 | $634K |
| Feb 11, 26 | Edward Morrow Atkinson IIIEVP, Chief Technical Ops. Off. | SELL | 1.8K | $460.43 | $806K |
| Feb 11, 26 | Jonathan BillerEVP and Chief Legal Officer | SELL | 1.9K | $460.43 | $886K |
| Feb 11, 26 | Mark E. BunnageEVP, Chief Scientific Officer | SELL | 2.0K | $460.43 | $931K |
| Feb 11, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 466 | $460.43 | $215K |
| Jan 7, 26 | Ourania TatsisEVP, Chief Reg. & Quality Off. | SELL | 4.5K | $474.99 | $2.1M |
| Jan 6, 26 | Charles F Wagner JrEVP, CO & FO | SELL | 9.5K | $461.00 | $4.4M |
| Dec 3, 25 | Jonathan BillerEVP and Chief Legal Officer | SELL | 347 | $449.00 | $156K |
| Dec 3, 25 | Jeffrey M LeidenExecutive Chairman | SELL | 15.7K | $455.22 | $7.1M |
Over the past 12 months, insiders at VERTEX PHARMACEUTICALS INC / MA filed 4 open-market purchases worth $5.8M and 91 sales worth $154.0M on VRTX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 2, 26.
14 different insiders at VERTEX PHARMACEUTICALS INC / MA filed open-market SEC Form 4 transactions on VRTX over the last 12 months.
InsiderTape plots every VRTX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every VERTEX PHARMACEUTICALS INC / MA insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →